Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization
- PMID:18252809
- DOI: 10.1124/jpet.107.133348
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization
Abstract
5-Hydroxytryptamine (5-HT)(2C) receptor agonists hold promise for the treatment of obesity. In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT(2C) full agonist. Lorcaserin bound to human and rat 5-HT(2C) receptors with high affinity (K(i) = 15 +/- 1 nM, 29 +/- 7 nM, respectively), and it was a full agonist for the human 5-HT(2C) receptor in a functional inositol phosphate accumulation assay, with 18- and 104-fold selectivity over 5-HT(2A) and 5-HT(2B) receptors, respectively. Lorcaserin was also highly selective for human 5-HT(2C) over other human 5-HT receptors (5-HT(1A), 5-HT(3), 5-HT(4C), 5-HT5(5A), 5-HT(6), and 5-HT(7)), in addition to a panel of 67 other G protein-coupled receptors and ion channels. Lorcaserin did not compete for binding of ligands to serotonin, dopamine, and norepinephrine transporters, and it did not alter their function in vitro. Behavioral observations indicated that unlike the 5-HT(2A) agonist (+/-)-1-(2,5-dimethoxy-4-phenyl)-2-aminopropane, lorcaserin did not induce behavioral changes indicative of functional 5-HT(2A) agonist activity. Acutely, lorcaserin reduced food intake in rats, an effect that was reversed by pretreatment with the 5-HT(2C)-selective antagonist 6-chloro-5-methyl-1-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl-carbamoyl]indoline (SB242,084) but not the 5-HT(2A) antagonist (R)-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol (MDL 100,907), demonstrating mediation by the 5-HT(2C) receptor. Chronic daily treatment with lorcaserin to rats maintained on a high fat diet produced dose-dependent reductions in food intake and body weight gain that were maintained during the 4-week study. Upon discontinuation, body weight returned to control levels. These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT(2C) receptor, with potential for the treatment of obesity.
Similar articles
- Directly Observable Behavioral Effects of Lorcaserin in Rats.Serafine KM, Rice KC, France CP.Serafine KM, et al.J Pharmacol Exp Ther. 2015 Dec;355(3):381-5. doi: 10.1124/jpet.115.228148. Epub 2015 Sep 17.J Pharmacol Exp Ther. 2015.PMID:26384326Free PMC article.
- Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist.Damjanoska KJ, Muma NA, Zhang Y, D'Souza DN, Garcia F, Carrasco GA, Kindel GH, Haskins KA, Shankaran M, Petersen BR, Van De Kar LD.Damjanoska KJ, et al.J Pharmacol Exp Ther. 2003 Mar;304(3):1209-16. doi: 10.1124/jpet.102.043489.J Pharmacol Exp Ther. 2003.PMID:12604698
- S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G.Millan MJ, et al.J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468. Epub 2011 Dec 16.J Pharmacol Exp Ther. 2012.PMID:22178752
- Lorcaserin: an investigational serotonin 2C agonist for weight loss.Hurren KM, Berlie HD.Hurren KM, et al.Am J Health Syst Pharm. 2011 Nov 1;68(21):2029-37. doi: 10.2146/ajhp100638.Am J Health Syst Pharm. 2011.PMID:22011982Review.
- Lorcaserin for the treatment of obesity.Redman LM, Ravussin E.Redman LM, et al.Drugs Today (Barc). 2010 Dec;46(12):901-10. doi: 10.1358/dot.2010.46.12.1556433.Drugs Today (Barc). 2010.PMID:21589947Free PMC article.Review.
Cited by
- Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.Higgins GA, Silenieks LB, Lau W, de Lannoy IA, Lee DK, Izhakova J, Coen K, Le AD, Fletcher PJ.Higgins GA, et al.Psychopharmacology (Berl). 2013 Apr;226(3):475-90. doi: 10.1007/s00213-012-2919-2. Epub 2012 Nov 25.Psychopharmacology (Berl). 2013.PMID:23184281
- Regioselective alkylation of 1,3,4,5-tetrahydrobenzo[d]azepin-2-one and biological evaluation of the resulting alkylated products as potentially selective 5-HT₂c agonists.Prajapati N, Giridhar R, Sinha A, Kanhed AM, Yadav MR.Prajapati N, et al.Mol Divers. 2015 Nov;19(4):653-67. doi: 10.1007/s11030-015-9600-8. Epub 2015 Apr 28.Mol Divers. 2015.PMID:25916735
- ACS chemical neuroscience molecule spotlight on Lorcaserin.Hopkins CR.Hopkins CR.ACS Chem Neurosci. 2010 Nov 17;1(11):718-9. doi: 10.1021/cn100059u.ACS Chem Neurosci. 2010.PMID:22778808Free PMC article.Review.
- The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ.Higgins GA, et al.Neuropsychopharmacology. 2012 Apr;37(5):1177-91. doi: 10.1038/npp.2011.303. Epub 2011 Dec 21.Neuropsychopharmacology. 2012.PMID:22189292Free PMC article.
- Drugs in the pipeline for the obesity market.Klonoff DC, Greenway F.Klonoff DC, et al.J Diabetes Sci Technol. 2008 Sep;2(5):913-8. doi: 10.1177/193229680800200525.J Diabetes Sci Technol. 2008.PMID:19885278Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases